Is RLAY or SANA more undervalued in 2026?

CirclFi compares Relay Therapeutics, Inc. (RLAY) and Sana Biotechnology, Inc. (SANA) using 13 institutional-grade valuation models. RLAY has a Quality of Company score of 6.0/10 while SANA scores 3.8/10.

Which is a better buy — RLAY or SANA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do RLAY and SANA valuations compare?

RLAY at $14.05 and SANA at $3.30 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

RLAY vs SANA Valuation Comparison 2026 — Intrinsic Value Analysis

RLAY

Biological Products, (No Diagnostic Substances)

Relay Therapeutics, Inc.

Quality

6.0

out of 10

Value Trap

SAFE

Price

$14.05

Last close

Models

12/13

Active

SANA

Biological Products, (No Diagnostic Substances)

Sana Biotechnology, Inc.

Quality

3.8

out of 10

Value Trap

LOW

Price

$3.30

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	RLAY Fair Value	RLAY Upside	SANA Fair Value	SANA Upside
Bayesian DCF	Intrinsic	$5.06	-64.0%	$0.87	-73.6%
Earnings Power Value	Intrinsic	$7.19	-52.5%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.79	-93.8%	$0.85	-74.3%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for RLAY vs SANA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

RLAY vs SANA — Which Stock Is More Undervalued?

RLAY scores higher with a 6.0/10 quality rating vs SANA's 3.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Relay Therapeutics, Inc. (RLAY) and Sana Biotechnology, Inc. (SANA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

RLAY currently trades at $14.05 with a QOC of 6.0/10, while SANA trades at $3.30 with a QOC of 3.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).